Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

NCT04631757 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: Camrelizumab + SOX + Radiotherapy

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Collaborators

[object Object]